Abstract
Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Keywords: Mesenchymal stem/stromal cells, cell therapy, graft versus host disease, immunomodulatory properties, regenerative medicine, advanced therapy medicinal product, transplantation, MSCs sources, clinical trials, clinical applications
Current Pharmaceutical Design
Title:Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy
Volume: 19 Issue: 13
Author(s): Laura de Girolamo, Enrico Lucarelli, Giulio Alessandri, Maria Antonietta Avanzini, Maria Ester Bernardo, Ettore Biagi, Anna Teresa Brini, Giovanna D’Amico, Franca Fagioli, Ivana Ferrero, Franco Locatelli, Rita Maccario, Mario Marazzi, Ornella Parolini, Augusto Pessina and Maria Luisa Torre ; Italian Mesenchymal Stem Cell Group (GISM)
Affiliation:
Keywords: Mesenchymal stem/stromal cells, cell therapy, graft versus host disease, immunomodulatory properties, regenerative medicine, advanced therapy medicinal product, transplantation, MSCs sources, clinical trials, clinical applications
Abstract: Mesenchymal stem cells (MSCs) were first isolated more than 50 years ago from the bone marrow. Currently MSCs may also be isolated from several alternative sources and they have been used in more than a hundred clinical trials worldwide to treat a wide variety of diseases. The MSCs mechanism of action is undefined and currently under investigation. For in vivo purposes MSCs must be produced in compliance with good manufacturing practices and this has stimulated research on MSCs characterization and safety. The objective of this review is to describe recent developments regarding MSCs properties, physiological effects, delivery, clinical applications and possible side effects.
Export Options
About this article
Cite this article as:
de Girolamo Laura, Lucarelli Enrico, Alessandri Giulio, Antonietta Avanzini Maria, Ester Bernardo Maria, Biagi Ettore, Teresa Brini Anna, D’Amico Giovanna, Fagioli Franca, Ferrero Ivana, Locatelli Franco, Maccario Rita, Marazzi Mario, Parolini Ornella, Pessina Augusto and ; Italian Mesenchymal Stem Cell Group (GISM) Luisa Torre Maria, Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell Therapy, Current Pharmaceutical Design 2013; 19 (13) . https://dx.doi.org/10.2174/1381612811319130015
DOI https://dx.doi.org/10.2174/1381612811319130015 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Editorial Board Member
Current Medical Imaging A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Development and Evaluation of poly(3-hydroxybutyrate-co-3-hydroxyvalerate) and Polycaprolactone Microparticles of Nimodipine
Current Pharmaceutical Design Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Preeclampsia: Placental Origins, New Predictors and New Therapeutic Strategies
Current Women`s Health Reviews Contrast-induced Nephropathy in Non-cardiac Vascular Procedures, A Narrative Review: Part 2
Current Vascular Pharmacology Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews High-pitch Dual-source CT Angiography before TAVI - the Value of ECG Gating
Current Medical Imaging The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Targeting Cancer Stem Cells with Natural Products
Current Drug Targets Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Cell and Gene Therapies in Cardiovascular Disease with Special Focus on the No Option Patient
Current Gene Therapy Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Matrix Metalloproteinases in Vascular Disease - A Potential Therapeutic Target?
Current Vascular Pharmacology The Role of Sympathetic Nervous System in the Progression of Chronic Kidney Disease in the Era of Catheter Based Sympathetic Renal Denervation
Current Clinical Pharmacology Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Patent Selections:
Recent Patents on Medical Imaging